Fusion Antibodies (LON:FAB) Stock Price Down 6.7% – Here’s Why

Fusion Antibodies plc (LON:FAB) fell 6.7% on Tuesday. The company traded as low as GBX 10.11 and last traded at GBX 10.50. Approximately 452,178 shares were traded during trading, an increase of 9% from the average daily volume of 415,391 shares. The stock had previously closed at GBX 11.25.

Fusion Antibodies Stock Down 6.7%

The firm has a market capitalization of £13.14 million, a price-to-earnings ratio of -10.50 and a beta of 1.24. The business has a 50 day simple moving average of GBX 11.04 and a 200-day simple moving average of GBX 11.95. The company has a debt-to-equity ratio of 20.41, a quick ratio of 2.36 and a current ratio of 2.82.

Fusion Antibodies (LON:FAB) last posted its quarterly earnings results on Monday, September 14th. The company reported GBX (1.20) EPS for the quarter. Fusion Antibodies had a negative return on equity of 97.87% and a negative net margin of 54.45%. On average, equities analysts expect that Fusion Antibodies plc will post -129.9999875 EPS for the current year.

Fusion Antibodies Company Profile

Fusion is a Belfast based contract research organisation (“CRO”) providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company’s ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion’s proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials.